Stockscreener 앱 받기
45.00
2.18%
0.96
시간 외 거래:
44.35
-0.65
-1.44%
Mirum Pharmaceuticals Inc 주식(MIRM)의 최신 뉴스
Alagille Syndrome Market Growth to Accelerate in Forecast - openPR.com
(MIRM) Investment Report - news.stocktradersdaily.com
11 Best Gene Therapy Stocks to Buy According to Analysts - Insider Monkey
Mirum Pharmaceuticals (MIRM) Down 1.9% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Mirum Pharmaceuticals Says Livmarli Approved in Japan for Pruritus - MarketScreener
LIVMARLI Now Approved In Japan For ALGS And PFIC - Marketscreener.com
LIVMARLI Now Approved in Japan for ALGS and PFIC - Business Wire
Mirum Pharmaceuticals: Set Fair For Share Price MomentumReversing My Sell Call (MIRM) - Seeking Alpha
Maintaining An 'Accumulate' Rating On Mirum Pharmaceuticals, Lots To Like (NASDAQ:MIRM) - Seeking Alpha
Exploring 3 High Growth Tech Stocks in the US Market - simplywall.st
(MIRM) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Mirum's Heavy Dependence on Livmarli for Revenues Remains a Woe - Nasdaq
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Looks Inexpensive But Perhaps Not Attractive Enough - simplywall.st
Mirum Pharmaceuticals SVP Jolanda Howe sells $107,342 in stock By Investing.com - Investing.com Australia
Mirum’s Rare Disease Strategy: A Blueprint For Sustainable Growth - News & Insights
Mirum Pharmaceuticals SVP Jolanda Howe sells $107,342 in stock - Investing.com
Mirum Pharmaceuticals CEO sells $1.2 million in stock By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals president sells $348k in stock - Investing.com India
Mirum Pharmaceuticals CEO sells $1.2 million in stock - Investing.com
Mirum Pharmaceuticals’ SVP Jolanda Howe sells $2.4 million in stock By Investing.com - Investing.com UK
Mirum Pharmaceuticals director Heron buys $24,214 in stock By Investing.com - Investing.com Australia
Mirum Pharmaceuticals director Heron buys $24,214 in stock - Investing.com India
Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older - Business Wire
Mirum Pharmaceuticals’ SWOT analysis: FDA nod boosts rare disease stock - Investing.com India
Mirum Pharmaceuticals director Heron buys $99,517 in stock - Investing.com India
Mirum Pharmaceuticals’ SWOT analysis: FDA nod boosts rare disease stock By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals director Heron buys $99,517 in stock By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals at Leerink Conference: Growth in Rare Diseases By Investing.com - Investing.com Canada
(MIRM) Proactive Strategies - Stock Traders Daily
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - WICZ
Mirum Pharmaceuticals Strengthens Growth Strategy with Strategic New Hires and Equity Incentives - StockTitan
Mirum Pharmaceuticals director Heron buys $83,661 in stock By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals director Heron buys $83,661 in stock - Investing.com India
MIRMMirum Pharmaceuticals Latest Stock News & Market Updates - StockTitan
Director’s Bold Move: Major Stock Purchase in Mirum Pharmaceuticals! - TipRanks
Mirum Pharmaceuticals’ president sells $676,928 in stock - Investing.com India
Mirum Pharmaceuticals’ president sells $676,928 in stock By Investing.com - Investing.com UK
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Bought by Rhumbline Advisers - Defense World
Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $72.00 - Defense World
Wall Street Analysts Predict a 26.18% Upside in Mirum Pharmaceuticals (MIRM): Here's What You Should Know - MSN
Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $72.00 at HC Wainwright - MarketBeat
Analyst Estimates: Here's What Brokers Think Of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) After Its Full-Year Report - Yahoo Finance UK
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates - MSN
(MIRM) Technical Data - Stock Traders Daily
2.00%
자본화:
|
볼륨(24시간):